Abivax SA
ABVX71.360USD
-0.585-0.81%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Abivax SA Compañía
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Información de la empresa
Símbolo de cotizaciónABVX
Nombre de la empresaAbivax SA
Fecha de salida a bolsaJun 26, 2015
Director ejecutivoMr. Marc De Garidel
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscal- -
Dirección7-11 Boulevard Haussmann
CiudadPARIS
Bolsa de valoresEuronext Paris
PaísFrance
Código postal75009
Teléfono33153830963
Sitio Webhttps://www.abivax.com/
Símbolo de cotizaciónABVX
Fecha de salida a bolsaJun 26, 2015
Director ejecutivoMr. Marc De Garidel
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick Malloy
Mr. Patrick Malloy
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Michael Ferguson
Mr. Michael Ferguson
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Board Secretary
Chief Financial Officer, Board Secretary
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Dr. Fabio Cataldi, M.D.
Dr. Fabio Cataldi, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Ana Sharma
Ms. Ana Sharma
Vice President - Global Head of Quality
Vice President - Global Head of Quality
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick Malloy
Mr. Patrick Malloy
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Michael Ferguson
Mr. Michael Ferguson
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Board Secretary
Chief Financial Officer, Board Secretary
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Dr. Fabio Cataldi, M.D.
Dr. Fabio Cataldi, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 18 de may
Actualizado: dom., 18 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.86%
Adar1 Capital Management LLC
3.00%
Cormorant Asset Management, LP
2.90%
Great Point Partners, LLC
2.23%
Other
78.78%
Accionistas
Accionistas
Proporción
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.86%
Adar1 Capital Management LLC
3.00%
Cormorant Asset Management, LP
2.90%
Great Point Partners, LLC
2.23%
Other
78.78%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
23.84%
Investment Advisor
10.96%
Investment Advisor/Hedge Fund
3.77%
Venture Capital
2.49%
Research Firm
2.19%
Other
56.74%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
74
31.84M
43.27%
-317.18K
2025Q1
74
31.82M
50.18%
-39.44K
2024Q4
67
29.91M
47.53%
+1.67M
2024Q3
53
27.43M
43.59%
-1.47M
2024Q2
50
28.12M
44.69%
-980.96K
2024Q1
45
23.37M
37.15%
+1.78M
2023Q4
32
21.64M
34.39%
+20.54M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
TCG Crossover Management, LLC
6.06M
9.55%
--
--
Mar 31, 2025
Deep Track Capital LP
3.58M
5.64%
--
--
Mar 31, 2025
Adar1 Capital Management LLC
2.21M
3.48%
+696.63K
+46.03%
Mar 31, 2025
Cormorant Asset Management, LP
2.13M
3.36%
--
--
Mar 31, 2025
Great Point Partners, LLC
1.64M
2.58%
-10.41K
-0.63%
Mar 31, 2025
Nantahala Capital Management, LLC
1.48M
2.34%
+46.95K
+3.27%
Mar 31, 2025
Citadel Advisors LLC
1.37M
2.17%
+518.18K
+60.56%
Mar 31, 2025
Franklin Advisers, Inc.
1.37M
2.16%
-95.01K
-6.48%
Mar 31, 2025
VR Adviser, LLC
1.35M
2.12%
--
--
Mar 31, 2025
Caligan Partners, LP
1.27M
2%
+516.95K
+68.73%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Innovator IBD Breakout Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
